Network Bio
2 known investors
Network Bio activates biobanks through securitization and capital infusion, providing research-grade data assets and operational infrastructure for precision medicine and biomedical research.
Investors · 2
Competitors · 8
by search overlap
bio11 shared keywordsBIO is the world's largest advocacy association representing biotechnology companies and research institutions across the United States and 30+ other nations. The organization facilitates industry networking through events, conferences, and partnering software while providing cost-savings programs and advocacy services for member companies.
Access BIO10 shared keywordsAccess Bio develops in vitro diagnostics technology, producing rapid diagnostic tests, molecular tests, analyzers, and COVID-19 tests (including PCR, serology, and antigen testing) to detect malaria and other diseases. It serves international public health agencies and organizations.
Bridgebio10 shared keywordsBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.
Engage Bio7 shared keywordsEngageBio develops DNA-based medicines using proprietary non-viral delivery technology to achieve extended therapeutic expression from a single dose with low manufacturing complexity.
Character Bio6 shared keywordsCharacter Bio is a patient-driven therapeutics company that combines genomics, longitudinal clinical and imaging data, and machine learning to identify genetic drivers of disease progression and develop new treatments, with a focus on polygenic diseases. It builds deeply-phenotyped patient cohorts by partnering with patients, providers, and scientists to enable clinical genomic research.
Nuvation Bio6 shared keywordsNuvation Bio is a global oncology company that develops novel cancer therapies through its own drug discovery programs and business development, serving cancer patients. Founded in 2018, it became a commercial-stage company in 2025.
Senti Biosciences6 shared keywordsSenti Bio develops cell and gene therapies for cancer and difficult-to-treat diseases using synthetic biology and engineered Gene Circuits to enhance precision, control, and selectivity in targeting tumor cells. The company is a clinical-stage biotech firm leveraging proprietary platform technology across multiple cell types and modalities.
Transition Bio6 shared keywordsTransition Bio applies methods from physics, chemistry, biology, and machine learning to study protein biophysics—including protein aggregation, self-assembly, and protein-protein interactions—for developing therapeutics targeting health and disease. The company is a platform-based biotherapeutics developer founded on academic research from the University of Cambridge.
Companies competing with Network Bio for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Network Bio do?
- Network Bio activates biobanks through securitization and capital infusion, providing research-grade data assets and operational infrastructure for precision medicine and biomedical research.
- Who are Network Bio's investors?
- Network Bio's investors include Artis Ventures, Breyer Capital.